Anti-IL-2 receptor antibodies versus anti-thymocyte globulin for induction therapy in kidney transplantation

Journal of the American Society of Nephrology

Volumn 20, Issue 6, 2009, Pages 1170-1171

  Mandelbrot, Didier ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CYCLOSPORIN; DACLIZUMAB; INTERLEUKIN 2 RECEPTOR ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

CELL PROLIFERATION; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DEATH; DIABETIC PATIENT; DRUG EFFICACY; EDITORIAL; FOLLOW UP; GLOMERULONEPHRITIS; GRAFT FAILURE; GRAFT REJECTION; GRAFT SURVIVAL; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; UNSPECIFIED SIDE EFFECT;

EID: 67449100081     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2009040389     Document Type: Editorial

References (13)

1. US Department of Health and Human Services: 2007 Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1997- 2006, Rockville, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation; 2007
2. Nashan B, Moore R, Amlot P, Schmidt AG, Abeywickrama K, Soulillou JP: Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group. Lancet 350: 1193-1198, 1997 (Pubitemid 127445091)
3. Vincenti F, Kirkman R, Light S, Bumgardner G, Pescovitz M, Halloran P, Neylan J, Wilkinson A, Ekberg H, Gaston R, Backman L, Burdick J: Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med 338: 161-165, 1998
4. Kahan BD, Rajagopalan PR, Hall M: Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group. Transplantation 67: 276-284, 1999 (Pubitemid 29066355)
5. Lawen JG, Davies EA, Mourad G, Oppenheimer F, Molina MG, Rostaing L, Wilkinson AH, Mulloy LL, Bourbigot BJ, Prestele H, Korn A, Girault D: Randomized double-blind study of immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetil-containing triple therapy in renal transplantation. Transplantation 75: 37-43, 2003 (Pubitemid 36139692)
6. Noel C, Abramowicz D, Durand D, Mourad G, Lang P, Kessler M, Charpentier B, Touchard G, Berthoux F, Merville P, Ouali N, Squifflet J-P, Bayle F, Wissing KM, Hazzan M: Daclizumab versus antithymocyte globulin in high-immunological- risk renal transplant recipients. J Am Soc Nephrol 20: 1385-1392, 2009
7. Lebranchu Y, Bridoux F, Buchler M, Le Meur Y, Etienne I, Toupance O, Hurault de Ligny B, Touchard G, Moulin B, Le Pogamp P, Reigneau O, Guignard M, Rifle G: Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy. Am J Transplant 2: 48-56, 2002
8. Mourad G, Rostaing L, Legendre C, Garrigue V, Thervet E, Durand D: Sequential protocols using basiliximab versus antithymocyte globulins in renal-transplant patients receiving mycophenolate mofetil and steroids. Transplantation 78: 584-590, 2004 (Pubitemid 39097106)
9. Kyllonen LE, Eklund BH, Pesonen EJ, Salmela KT: Single bolus antithymocyte globulin versus basiliximab induction in kidney transplantation with cyclosporine triple immunosuppression: Efficacy and safety. Transplantation 84: 75-82, 2007 (Pubitemid 47094645)
10. Brennan DC, Daller JA, Lake KD, Cibrik D, Del Castillo D: Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med 355: 1967-1977, 2006 (Pubitemid 44708016)
11. Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B: Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 4: 378-383, 2004 (Pubitemid 38282293)
12. Brennan DC, Schnitzler MA: Long-term results of rabbit antithymocyte globulin and basiliximab induction. N Engl J Med 359: 1736-1738, 2008
13. Patlolla V, Zhong X, Reed GW, Mandelbrot DA: Efficacy of anti-IL-2 receptor antibodies compared to no induction and to antilymphocyte antibodies in renal transplantation. Am J Transplant 7: 1832-1842, 2007 (Pubitemid 46905449)